A new review of preclinical studies suggests GLP-1 drugs like Ozempic may reduce key proteins linked to Alzheimer’s disease.

The FDA has approved Auvelity for treating agitation in patients with dementia due to Alzheimer’s disease, Axsome ...

Oral NMDA receptor antagonist gets an expanded indication ...

Researchers at UC San Diego say they recently uncovered new insights into a protein that has emerged as a potential molecular “switch” that may determine whether Alzheimer’s-like brain changes lead to ...

The Food and Drug Administration (FDA) approved the drug Auvelity this week for the treatment of agitation in adults with ...

Researchers at the Indiana University School of Medicine have developed a new way to read the brain's "energy network ...

Menopause happens to every woman, and it may hold clues as to why women are at a greater risk for Alzheimer’s disease. Yale ...

Care at home often lacks the clinical leadership and structure necessary to be safe, consistent, and sustainable.

Discusses Approval of AUVELITY for Agitation Associated With Dementia Due to Alzheimer's Disease May 1, 2026 8:00 ...

New research from Mayo Clinic shows that subtle biological changes may begin years before Alzheimer's symptoms appear.

Subtle biological changes linked to Alzheimer's disease may begin as early as the late 50s—decades before memory loss or ...

"Auvelity becomes first non-antipsychotic approved for Alzheimer’s agitation" was originally created and published by ...